Verici Dx Regulatory News (VRCI)

Verici Dx plc

("Verici Dx" or the "Company")

Board Change

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that James McCullough, Non-Executive Director, has resigned from the Board with immediate effect to focus on his role as CEO of Renalytix plc.

The Company has begun its search for a replacement Non-Executive Director to join the Board and will provide an update in due course.

Sara Barrington, Chief Executive Officer, said: "It has been a pleasure to work alongside James for the last five years and I would like to thank James for his expertise, advice and contribution to the Company. I wish James every success and all the best for the future."

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.